Cabenuva is an injectable HIV treatment given once a month or once every two months, replacing the need for daily pills. It combines two antiretroviral medications, cabotegravir and rilpivirine, delivered as intramuscular injections during a clinic visit. The FDA has approved it for adults and adolescents aged 12 and older (weighing at least 35 kg) whose virus is already well controlled on their current oral HIV regimen.
Who Cabenuva Is For
Cabenuva is not a first-line treatment for someone newly diagnosed with HIV. It’s designed for people who are already virologically suppressed, meaning their viral load is below 50 copies per milliliter on a stable daily pill regimen. You also need to have no history of treatment failure and no known resistance to either of the two drugs in Cabenuva.
In practical terms, this means your current HIV medications are working well and you want to switch from daily pills to periodic injections. If you’ve had past regimens fail or your virus carries certain resistance mutations, Cabenuva may not be effective for you. Your provider will review your treatment history and resistance testing before making the switch.
It’s worth noting that Cabenuva is strictly for HIV treatment, not prevention. A related product called Apretude uses one of the same ingredients (cabotegravir alone) as injectable pre-exposure prophylaxis, or PrEP, for people who are HIV-negative. The two serve very different purposes.
How It Works
Cabenuva attacks HIV at two different points in its replication cycle. Cabotegravir is an integrase inhibitor. It blocks the enzyme HIV uses to insert its genetic material into your cells’ DNA, which is a critical step the virus needs to reproduce. Rilpivirine works earlier in the process by disabling reverse transcriptase, the enzyme HIV uses to convert its RNA into DNA in the first place. By targeting two separate steps, the combination makes it much harder for the virus to replicate or develop resistance.
Dosing Schedule and What to Expect
Before starting injections, your provider may have you take oral versions of both drugs (one pill of each, daily with food) for about a month. This optional lead-in period helps confirm you tolerate the medications without significant side effects before committing to long-acting injections. Some people skip this step and go directly to injections.
Cabenuva is available on two schedules:
- Monthly dosing: You receive a pair of loading-dose injections at your first visit, then a slightly lower maintenance dose every month. There’s a 7-day window on either side of your scheduled date, giving you some flexibility.
- Every-2-month dosing: You receive loading-dose injections at two consecutive monthly visits, then switch to injections every two months. The same 7-day scheduling window applies.
Each visit involves two separate intramuscular injections, one for each drug, administered in the gluteal muscle (buttock) by a healthcare provider. You cannot give yourself these injections at home. The clinic visit itself is typically brief once the injections are prepared.
How Well It Works
The ATLAS-2M trial, published in The Lancet HIV, followed over 1,000 participants for 96 weeks to compare the monthly and every-2-month schedules. Both performed well: 91% of those on the every-2-month schedule and 90% of those on the monthly schedule maintained viral loads below 50 copies per milliliter at 96 weeks. Only about 1 to 2% of participants in either group experienced confirmed virologic failure. The every-2-month schedule met statistical non-inferiority compared to monthly dosing, meaning it works just as well for the vast majority of people.
These results are comparable to what you’d expect from a well-functioning daily oral regimen, which is exactly the point. Cabenuva isn’t meant to work better than pills. It’s meant to work equally well while eliminating the daily routine.
Common Side Effects
The most frequently reported side effect is a reaction at the injection site: pain, swelling, or hardness where the needle went in. For most people, injection site discomfort is mild to moderate and resolves within a few days. Some people also experience fever, fatigue, headache, or muscle pain shortly after their injections, similar to how you might feel after a vaccine. These symptoms tend to be most noticeable after the first few injections and often become less bothersome over time.
Because the medication is long-acting and stays in your body for weeks after each injection, any side effects that do occur can’t simply be stopped by skipping a dose. This is one reason the optional oral lead-in period exists: it lets you test your tolerance with a short-acting form of the drugs before committing to the injectable version.
Important Limitations
Cabenuva can interact with medications that speed up the body’s metabolism of its active ingredients. Certain drugs used to treat tuberculosis, seizures, and other conditions are strong enzyme inducers and can lower Cabenuva’s drug levels enough to risk treatment failure. Your provider will need a complete list of everything you take, including supplements, before prescribing it.
Sticking to the injection schedule is critical. Because Cabenuva replaces your entire HIV regimen, a missed or significantly delayed injection means you have no antiretroviral protection. Unlike a missed daily pill that you can simply take the next day, a lapsed injection can leave drug levels low for weeks, increasing the risk of viral rebound and potential resistance. If you anticipate difficulty making clinic appointments on a regular schedule, that’s an important factor to discuss with your provider before switching.